Valuation: Satellos Bioscience Inc.

Market Cap 199M 174M 161M 149M 282M 19.01B 287M 1.92B 755M 9.37B 748M 732M 32.2B P/E 2026 *
-5.49x
P/E 2027 * -5.85x
Enterprise Value 106M 92.44M 85.27M 78.75M 149M 10.08B 152M 1.02B 400M 4.97B 397M 388M 17.07B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
93.51%
Yield 2026 *
-
Yield 2027 * -
1 day+1.88%
1 week+24.01%
Current month+26.92%
1 month+68.70%
3 months+49.50%
6 months+35.03%
Current year+70.83%
1 week 10.86
Extreme 10.86
14.15
1 month 7.76
Extreme 7.76
14.15
Current year 7.67
Extreme 7.67
18.98
1 year 6.36
Extreme 6.36
18.98
3 years 3.48
Extreme 3.48
18.98
5 years 2.58
Extreme 2.58
22.8
10 years 2.58
Extreme 2.58
22.8
Manager TitleAgeSince
Chief Executive Officer 70 01/03/2018
Chief Tech/Sci/R&D Officer - 01/05/2018
Director of Finance/CFO - 01/09/2023
Director TitleAgeSince
Chairman 59 01/07/2018
Director/Board Member 50 01/03/2018
Director/Board Member 70 01/07/2012
Date Insider Type Main position Quantity % Market Cap.
18/06Buy

Director

15,000 0.0720%
07/04Option

Founder

108,630 0.7027%
07/04Buy

Director

5,500 0.0356%
Change 5-day change 1-year change 3-year change Capi.($)
+1.88%+24.01%+94.40%+139.89% 199M
+1.84%-0.66%+59.82%+92.96% 54.88B
-4.14%-8.06%+58.96%+118.67% 54.63B
-2.24%+3.59%+17.75%+477.47% 25.06B
-1.60%-6.21%-18.96%-15.21% 23.14B
+2.43%+1.06%+42.44%-1.27% 19.87B
-3.19%0.00%+35.60%-26.98% 17.55B
-6.84%+2.18%+195.12%+357.18% 16.5B
+8.74%+3.51%+51.91%+726.40% 15.75B
-1.05%+1.16%+25.95%+194.27% 14.2B
Average -0.42%+2.15%+56.30%+206.34% 24.18B
Weighted average by Cap. -0.89%-1.43%+51.30%+177.11%

Financials

2026 *2027 *
Net sales - -
Net income -48.32M -42.27M -38.99M -36.01M -68.32M -4.61B -69.47M -466M -183M -2.27B -181M -177M -7.81B -56.57M -49.48M -45.64M -42.15M -79.98M -5.4B -81.33M -545M -214M -2.66B -212M -208M -9.14B
Net Debt -93.65M -81.92M -75.56M -69.78M -132M -8.93B -135M -903M -355M -4.4B -352M -344M -15.13B -111M -97.4M -89.84M -82.97M -157M -10.62B -160M -1.07B -422M -5.23B -418M -409M -17.99B
Logo Satellos Bioscience Inc.
Satellos Bioscience Inc. is a Canada-based clinical-stage drug development company. The Company is focused on restoring natural muscle repair and regeneration in degenerative muscle diseases. Through its research, the Company has developed SAT-3247, a first-of-its-kind, orally administered small molecule drug designed to address deficits in muscle repair and regeneration. SAT-3247 targets AAK1, a key protein that has identified as capable of replacing the signal normally provided by dystrophin in muscle stem cells to effect repair and regeneration. It is also leveraging its proprietary discovery platform MyoReGenX to identify additional muscle diseases or injury conditions where restoring muscle repair and regeneration may have therapeutic benefit and represent future clinical development opportunities. With this platform, the Company is building a pipeline of therapeutics to correct muscle stem cell polarity and promote the body’s innate muscle repair and regeneration process.
Employees
20
Date Price Change Volume
10/07/26 CAD 13.53 +1.88% 26,751
09/07/26 CAD 13.28 +5.23% 91,570
08/07/26 CAD 12.62 +9.26% 219,239
07/07/26 CAD 11.55 -0.09% 11,729
06/07/26 CAD 11.56 +5.96% 13,838
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
13.53CAD
Average target price
17.67CAD
Spread / Average Target
+30.57%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MSCL Stock